These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7831807)

  • 1. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.
    Jacobsen H; Yasargil K; Winslow DL; Craig JC; Kröhn A; Duncan IB; Mous J
    Virology; 1995 Jan; 206(1):527-34. PubMed ID: 7831807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959.
    Eberle J; Bechowsky B; Rose D; Hauser U; von der Helm K; Gürtler L; Nitschko H
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):671-6. PubMed ID: 7576926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.
    Jacobsen H; Hänggi M; Ott M; Duncan IB; Owen S; Andreoni M; Vella S; Mous J
    J Infect Dis; 1996 Jun; 173(6):1379-87. PubMed ID: 8648209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Partaledis JA; Yamaguchi K; Tisdale M; Blair EE; Falcione C; Maschera B; Myers RE; Pazhanisamy S; Futer O; Cullinan AB
    J Virol; 1995 Sep; 69(9):5228-35. PubMed ID: 7636964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase.
    Turriziani O; Antonelli G; Jacobsen H; Mous J; Riva E; Pistello M; Dianzani F
    Acta Virol; 1994 Oct; 38(5):297-8. PubMed ID: 7726006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials.
    Jacobsen H; Haenggi M; Ott M; Duncan IB; Andreoni M; Vella S; Mous J
    Antiviral Res; 1996 Jan; 29(1):95-7. PubMed ID: 8721556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.
    Patick AK; Rose R; Greytok J; Bechtold CM; Hermsmeier MA; Chen PT; Barrish JC; Zahler R; Colonno RJ; Lin PF
    J Virol; 1995 Apr; 69(4):2148-52. PubMed ID: 7884862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
    Pazhanisamy S; Stuver CM; Cullinan AB; Margolin N; Rao BG; Livingston DJ
    J Biol Chem; 1996 Jul; 271(30):17979-85. PubMed ID: 8663409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.
    Smidt ML; Potts KE; Tucker SP; Blystone L; Stiebel TR; Stallings WC; McDonald JJ; Pillay D; Richman DD; Bryant ML
    Antimicrob Agents Chemother; 1997 Mar; 41(3):515-22. PubMed ID: 9055985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors.
    Maschera B; Furfine E; Blair ED
    J Virol; 1995 Sep; 69(9):5431-6. PubMed ID: 7636988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site.
    Sardana VV; Schlabach AJ; Graham P; Bush BL; Condra JH; Culberson JC; Gotlib L; Graham DJ; Kohl NE; LaFemina RL
    Biochemistry; 1994 Mar; 33(8):2004-10. PubMed ID: 8117657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of drug resistance to HIV-1 protease inhibitors.
    Ridky T; Leis J
    J Biol Chem; 1995 Dec; 270(50):29621-3. PubMed ID: 8530341
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.
    Patick AK; Mo H; Markowitz M; Appelt K; Wu B; Musick L; Kalish V; Kaldor S; Reich S; Ho D; Webber S
    Antimicrob Agents Chemother; 1996 Feb; 40(2):292-7. PubMed ID: 8834868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.
    Tisdale M; Myers RE; Maschera B; Parry NR; Oliver NM; Blair ED
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1704-10. PubMed ID: 7486905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
    Gulnik SV; Suvorov LI; Liu B; Yu B; Anderson B; Mitsuya H; Erickson JW
    Biochemistry; 1995 Jul; 34(29):9282-7. PubMed ID: 7626598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
    Mammano F; Trouplin V; Zennou V; Clavel F
    J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.